NEW YORK - Pfizer Inc. and BioNTech recently announced the results of their COVID-19 vaccine among children aged 5 to 11 years.
They said that the COVID-19 vaccine generates a robust immune response in 5 to 11-year-olds individuals and now looking forward to regulatory authorization as soon as possible to use the shot in children of that age group in the United States, Europe and elsewhere.
The companies also added that the safety profile was also similar to the older age group.